ImmuPharma (LON:IMM) Trading Down 5.7% – Should You Sell?

ImmuPharma plc (LON:IMM)’s share price traded down 5.7% during mid-day trading on Thursday . The stock traded as low as GBX 4.20 ($0.05) and last traded at GBX 4.43 ($0.06). 4,153,455 shares were traded during mid-day trading, a decline of 79% from the average session volume of 19,996,625 shares. The stock had previously closed at GBX 4.70 ($0.06).

ImmuPharma Trading Down 7.8 %

The company has a market capitalization of £16.52 million, a PE ratio of -396.80 and a beta of 1.53. The firm’s 50-day simple moving average is GBX 2.67 and its 200-day simple moving average is GBX 2.01.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.